

09/554, 772

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:14:31 ON 24 AUG 2006

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 12:15:09 ON 24 AUG 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 12:15:09 ON 24 AUG 2006

FILE 'CAPLUS' ENTERED AT 12:15:09 ON 24 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:15:09 ON 24 AUG 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:15:09 ON 24 AUG 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s chlamydia and platelet aggrega?  
L1 220 CHLAMYDIA AND PLATELET AGGREGA?

=> s l1 and chamydia pneum? and ketolide  
L2 0 L1 AND CHAMYDIA PNEUM? AND KETOLIDE

=> s l1 and chamydia pneum?  
L3 0 L1 AND CHAMYDIA PNEUM?

=> s l1 and chlamydia pneum? and ketolid  
L4 0 L1 AND CHLAMYDIA PNEUM? AND KETOLID

=>  
<-----User Break----->

=> s l1 and chlamydia pneum?  
L5 70 L1 AND CHLAMYDIA PNEUM?

=> s l5 and atheroscleros?  
L6 57 L5 AND ATHEROSCLEROS?

=> s l6 and ketoli  
L7 0 L6 AND KETOLI

=> s l6 and ketol?  
L8 5 L6 AND KETOL?

=> dup rem 8  
ENTER L# LIST OR (END):18  
'8' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS, USPATFULL'  
You have entered a file name of duplicates to keep that is not  
referenced by any of the L#s specified for this DUPLICATE command.  
The file names of duplicates that can be kept are listed above.  
Please enter one of these file names.

=> d l8 bib abs 1-8

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:80343 CAPLUS  
 DN 140:122836  
 TI Use of 2,3-alkylcarbonyloxybenzoic acids, derivatives and analogues  
 therefrom in the treatment of tissue and cellular dysfunction, damage and  
 injury in mammals  
 IN Stec, Karen; Rubinstein, Israel; Eiznhamer, David; Xu, Ze-qu; Flavin,  
 Michael  
 PA USA  
 SO U.S. Pat. Appl. Publ., 6 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004019022	A1	20040129	US 2003-622302	20030718
	WO 2004010989	A1	20040205	WO 2003-US23644	20030718
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003252178	A1	20040216	AU 2003-252178	20030718
	EP 1539132	A1	20050615	EP 2003-772019	20030718
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-398523P	P	20020725		
	WO 2003-US23644	W	20030718		

AB A method for the treatment of cellular and tissue damage is disclosed.  
 The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid  
 and salts thereof for the prevention and treatment of dysfunction, damage,  
 and/or injuries to organs, tissues and/or cells in human or animal  
 subjects caused by diseases, infections and conditions such as pneumonia,  
 coronavirus, multiple transfusions, trauma, ischemic-reperfusion  
 dysfunctions, stroke, drug overdose, and severe acute respiratory  
 syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in  
 combination with other therapeutic agents such as antibiotics. The acid  
 may be administered in any practical delivery form, and in free acid or  
 buffered form.

L8 ANSWER 2 OF 5 USPATFULL on STN  
 AN 2005:165984 USPATFULL  
 TI Regimen for the administration of rifamycin-class antibiotics  
 IN Michaelis, Arthur F., Devon, PA, UNITED STATES  
 Cabana, Bernard E., Montgomery Village, MD, UNITED STATES  
 PI US 2005143409 A1 20050630  
 AI US 2004-948608 A1 20040923 (10)  
 PRAI US 2003-505855P 20030924 (60)  
 DT Utility  
 FS APPLICATION  
 LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
 CLMN Number of Claims: 45  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 1414  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention features an ascending dose regimen for the administration  
 of rifamycin-class antibiotics. The dosing regimen can be used to treat

bacterial infections and diseases related to infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 5 USPATFULL on STN  
AN 2005:143867 USPATFULL  
TI Rifalazil formulations  
IN Michaelis, Arthur F., Devon, PA, UNITED STATES  
PI US 2005123602 A1 20050609  
AI US 2004-950917 A1 20040927 (10)  
PRAI US 2003-506107P 20030925 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 1636

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features pharmaceutical compositions including rifalazil and a micelle-forming excipient and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 5 USPATFULL on STN  
AN 2004:203948 USPATFULL  
TI Rifalazil compositions and therapeutic regimens  
IN Cabana, Bernard E., Montgomery Village, MD, UNITED STATES  
Michaelis, Arthur F., Devon, PA, UNITED STATES  
Magnant, Gary P., Topsfield, MA, UNITED STATES  
Sayada, Chalom B., Luxembourg City, LUXEMBOURG  
PI US 2004157840 A1 20040812  
AI US 2003-668792 A1 20030923 (10)  
PRAI US 2002-412958P 20020923 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 7 Drawing Page(s)  
LN.CNT 1369

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features low-dosage rifalazil compositions and therapeutic regimens which are useful for the treatment of bacterial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 5 USPATFULL on STN  
AN 2004:45028 USPATFULL  
TI Intravenous rifalazil formulation and methods of use thereof  
IN Michaelis, Arthur F., Devon, PA, UNITED STATES  
Sayada, Chalom, Luxembourg City, LUXEMBOURG  
Cabana, Bernard E., Montgomery Village, MD, UNITED STATES  
PI US 2004034021 A1 20040219  
AI US 2003-453155 A1 20030603 (10)  
PRAI US 2002-385532P 20020603 (60)  
US 2002-406873P 20020829 (60)  
US 2002-412958P 20020923 (60)  
US 2003-444570P 20030203 (60)  
DT Utility  
FS APPLICATION  
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110  
CLMN Number of Claims: 62  
ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 1942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features intravenous dosage formulations of rifalazil and methods of treating disease by intravenous administration of rifalazil.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d hid

'HID' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):his

'HIS' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):filedefault

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:80343 CAPLUS

DN 140:122836

TI Use of 2,3-alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals

IN Stec, Karen; Rubinstein, Israel; Eiznhamer, David; Xu, Ze-qu; Flavin, Michael

PA USA

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004019022	A1	20040129	US 2003-622302	20030718
	WO 2004010989	A1	20040205	WO 2003-US23644	20030718
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003252178	A1	20040216	AU 2003-252178	20030718
	EP 1539132	A1	20050615	EP 2003-772019	20030718
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-398523P	P	20020725		
	WO 2003-US23644	W	20030718		

=> d his

(FILE 'HOME' ENTERED AT 12:14:31 ON 24 AUG 2006)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:15:09 ON

24 AUG 2006

L1 220 S CHLAMYDIA AND PLATELET AGGREGA?  
L2 0 S L1 AND CHAMYDIA PNEUM? AND KETOLIDE  
L3 0 S L1 AND CHAMYDIA PNEUM?  
L4 0 S L1 AND CHLAMYDIA PNEUM? AND KETOLID  
L5 70 S L1 AND CHLAMYDIA PNEUM?  
L6 57 S L5 AND ATHEROSCLEROS?  
L7 0 S L6 AND KETOLI  
L8 5 S L6 AND KETOL?

=> dup rem l6

PROCESSING COMPLETED FOR L6

L9 47 DUP REM L6 (10 DUPLICATES REMOVED)

=> s l9 and 1997/pn

'PN' IS NOT A VALID FIELD CODE

L10 0 L9 AND 1997/PN

=> s l9 and 1997/py

L11 0 L9 AND 1997/PY

=> s l9 and chlamydia (4a) platelet

L12 1 L9 AND CHLAMYDIA (4A) PLATELET

=> d l12 bib abs

L12 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2003:571507 BIOSIS

DN PREV200300575234

TI Chlamydia pneumoniae binds to platelets and triggers  
P-selectin expression and aggregation: A causal role in cardiovascular  
disease?.

AU Kalvegren, Hanna [Reprint Author]; Majeed, Meytham; Bengtsson, Torbjorn

CS Division of Medical Microbiology, Department of Molecular and Clinical  
Medicine, Faculty of Health Sciences, Linkoping University, SE-581 85,  
Linkoping, Sweden  
hanjo@imk.liu.se

SO Arteriosclerosis Thrombosis and Vascular Biology, (September 2003) Vol.  
23, No. 9, pp. 1677-1683. print.

ISSN: 1079-5642 (ISSN print).

DT Article

LA English

ED Entered STN: 10 Dec 2003

Last Updated on STN: 10 Dec 2003

AB Objective-Evidence linking Chlamydia pneumoniae to  
atherosclerotic cardiovascular disease is expanding. Platelets are  
considered to play an essential role in cardiovascular diseases; however,  
so far platelets have not been associated with an infectious cause of  
atherosclerosis. This study aims to clarify the interaction  
between C pneumoniae and platelets and possibly present a novel mechanism  
in the pathogenesis of atherosclerosis. Methods and Results-The  
effects of C pneumoniae on platelet aggregation and  
secretion were assessed with lumiaggregometry, and the ability of C  
pneumoniae to bind to platelets and stimulate expression of P-selectin was  
analyzed with flow cytometry. We found that C pneumoniae, at a  
chlamydia:platelet ratio of 1:15, adheres to platelets  
and triggers P-selectin expression after 1 minute and causes an extensive  
aggregation and ATP secretion after 20 minutes of incubation. Inhibition  
of glycoprotein IIb/IIIa with Arg-Gly-Asp-Ser or abciximab markedly  
reduced C pneumoniae-induced platelet aggregation.  
Exposure of C pneumoniae to polymyxin B, but not elevated temperature,  
abolished the stimulatory effects on platelet activation, suggesting that  
chlamydial lipopolysaccharide has an active role. In contrast, other  
tested bacteria had no or only moderate effects on platelet functions.

Conclusion-Our findings demonstrate a new concept of how C pneumoniae activates platelets and thereby may cause atherosclerosis and thrombotic vascular occlusion.

=> d his

(FILE 'HOME' ENTERED AT 12:14:31 ON 24 AUG 2006)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:15:09 ON 24 AUG 2006

L1 220 S CHLAMYDIA AND PLATELET AGGREGA?  
L2 0 S L1 AND CHAMYDIA PNEUM? AND KETOLIDE  
L3 0 S L1 AND CHAMYDIA PNEUM?  
L4 0 S L1 AND CHLAMYDIA PNEUM? AND KETOLID  
L5 70 S L1 AND CHLAMYDIA PNEUM?  
L6 57 S L5 AND ATHEROSCLEROS?  
L7 0 S L6 AND KETOLI  
L8 5 S L6 AND KETOL?  
L9 47 DUP REM L6 (10 DUPLICATES REMOVED)  
L10 0 S L9 AND 1997/PN  
L11 0 S L9 AND 1997/PY  
L12 1 S L9 AND CHLAMYDIA (4A) PLATELET

=> s 19 and 1997/pd

4 FILES SEARCHED...

L13 0 L9 AND 1997/PD

=>